Advanced Cell Diagnostics’ Pharma Assay Services provides RNAscope® in situ gene expression analysis for target validation, target safety assessment and biomarker discovery to support preclinical research in every therapeutic area, as well as clinical biomarker development for oncology.
We provide target expression analysis that is not possible by any other means. RNAscope® Assay is able to detect any mRNA, including specific isoforms, novel exon junctions, SNPs and mutations, as well as viral vectors and codon-optimized transgene expression in essentially any fixed human and preclinical animal model tissue while presenving morphological context. Our Pharma Assay Services is valued for the high quality of data and analysis coupled with fast turnaround time, its flexibility and capacity to accommodate studies of any scale.
Our expertise is based on having delivered 10,000’s of marker stained slides and provided tissue-based expression information on well over 500 targets in more than 150 tissue types. We have nearly 9000 target RNA-specific probes in our catalog and can design probes for any mRNA in 2 weeks. With over 5 years of experience as a contract research organization (CRO) specializing in RNAscope® ISH, we have supported hundreds of clinical and pre-clinical projects with every major biopharma in the US and globally. Each project is individually tailored and managed by our team of scientists, specialists, board certified pathologists, and data analysis experts.